Sökning: id:"swepub:oai:gup.ub.gu.se/186054" >
Late divergence of ...
Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications
-
- Bergh Thorén, Fredrik, 1976 (författare)
- Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine
-
- Anderson, Harald (författare)
- Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Strannegård, Örjan, 1936 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine
-
(creator_code:org_t)
- 2013-08-24
- 2013
- Engelska.
-
Ingår i: Cancer Immunology Immunotherapy. - : Springer Science and Business Media LLC. - 0340-7004 .- 1432-0851. ; 62:10, s. 1547-1551
- Relaterad länk:
-
https://lup.lub.lu.s...
-
visa fler...
-
https://portal.resea... (primary) (free)
-
http://dx.doi.org/10...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Late divergence of survival curves of treated patients and controls is commonly seen in successful cancer immunotherapy trials. Although late survival curve divergence may be caused by a delayed action of therapy, it may also be related to early effects of the treatment. We suggest that late survival divergence most often reflects a specific benefit of therapy for patients who suffer from a comparatively slow progression of disease. The occurrence of delayed survival curve divergence has important implications for the statistical analysis of immunotherapy trials. Thus, it leads to non-proportional hazard ratios that make commonly used statistical tests, e.g., the logrank test, suboptimal. It is therefore suggested that the statistical analysis of immunotherapy trials primarily should be based on a test that compares the survival curves at or after a prespecified, fixed, late time point.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Immunotherapy
- Survival analysis
- Kaplan-Meier
- Treatment outcome
- Late divergence
- Statistical
- RESISTANT PROSTATE-CANCER
- RANDOMIZED PHASE-III
- METASTATIC MELANOMA
- CUTANEOUS MELANOMA
- LOGRANK TEST
- END-POINTS
- FOLLOW-UP
- VACCINE
- VITESPEN
- BLOCKADE
- Late
- divergence
- Statistical models
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas